© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
November 08, 2020
Dr. David Goodman discusses the gaps in ADHD treatment.
November 06, 2020
Researchers find 1 lipid class and 6 miRNAs differed significantly between different treatment groups.
It is possible to diagnose patients with ADHD as young as 2 years old.
AXS-05 significantly relieved agitation, demonstrating a change from baseline in the CMAI total score of 15.4 compared to 11.5 for the placebo.
Dr. David Goodman will present 5 times during NEI about different ADHD issues and topics.
In the study, investigators tested the impact of the study drug in a rerandomized patient population that previously received a placebo.
November 05, 2020
A large portion of communication is non-verbal.
Clinicians rated 82% of the patients receiving the study drug and 46% in the placebo group as either much improved or very much improved on the Clinical Global Impression of Improvement scale.
Attempts to use neuroimaging to screen for ADHD in the past have failed.
Both methylphenidate PRC-063 and lisdexamfetamine led to improved performances for drivers with ADHD.
Gina Poe, PhD: How Psychiatric Diseases Impact Sleep Health
Madeline Belk, PharmD, Discusses Oral Vancomycin as a First-Line CDI Therapy
Low Prevalence of Keratosis Pilaris in Patients with Atopic Dermatitis